NasdaqGS:NTRABiotechs
Natera (NTRA): Assessing Valuation After AI Platform Launch and Positive Phase III Signatera Results
If you’re holding or thinking about Natera (NTRA), this week’s news could be a meaningful signal for your watchlist. The company just launched a new proprietary AI foundation model platform, built on one of the largest multimodal oncology datasets available, and featuring advanced applications for clinical decision support and therapeutic discovery. In addition, Natera reported strong phase III trial results for its Signatera ctDNA test in muscle-invasive bladder cancer, a step that could...